Breaking News

SCYNEXIS Appoints Infectious Disease Expert

By Kristin Brooks | February 24, 2014

Sable brings extensive clinical development experience

Carole Sable, M.D., has been appointed chief medical officer at SCYNEXIS. Dr. Sable most recently served as vice president at Merck & Co., initially as franchise integrator in Infectious Diseases, and more recently as vice president of project leadership and management in neurosciences and ophthalmology.
Prior to Merck, Dr. Sable served as chief medical officer of Novexel SA and president of Novexel Inc., the U.S. subsidiary, where she was responsible for the clinical development of two antibacterial programs, which led to the acquisition of Novexel SA by AstraZeneca. Previously, she was executive director of Infectious Disease and Vaccines Clinical Research at Merck, where she was responsible for anti-bacterial, antifungal and vaccine development programs, including the clinical development of the antifungal agent Cancidas.
“Carole brings to SCYNEXIS a significant tenure in the clinical development of infectious disease products, both as a clinician and in various corporate roles,” said Dr. Yves Ribeill, SCYNEXIS president and chief executive officer. “We look forward to her contributions as we continue to advance our lead candidate, SCY-078, a novel oral and intravenous antifungal compound, as well as our anti-viral platform.”
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision